Neximmune Inc (NEXI) Peer Comparison
$0.00
$-0.21
(-99.95%)
As on 26-Aug-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 16,614 | 17,326 | 13,400 | 12,305 |
Revenue ($ Mln) |
2 | 1,054 | 2,782 | 2,436 | 670 |
Net Profit ($ Mln) |
-20.62 | 755.85 | 491.50 | 860.62 | -319.95 |
Net Margin (%) |
-972.24 | 71.69 | 17.67 | 35.33 | -47.79 |
RoE (%) |
-930.73 | -- | 110.09 | 42.98 | -71.14 |
Price to Earnings |
-- | 19.38 | 36.49 | 17.01 | -- |
Price-To-Book |
0.00 | 10.05 | 39.43 | 7.27 | 26.44 |
Income Statement ($ Mln)
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2.12 | 266.72 | 1,885.84 | 1,830.21 | 240.74 |
|
Cost of Revenue
|
0.46 | 44.40 | 1,361.34 | 72.55 | 12.49 |
|
Gross Profit
|
-1.02 | 222.32 | 524.51 | 1,757.66 | 228.24 |
|
Operating Expenses
|
20.82 | 677.86 | 187.68 | 1,586.78 | 433.24 |
|
Operating Profit (EBIT)
|
-20.94 | -455.54 | 336.83 | 170.89 | -205.00 |
|
Other Income
|
0.00 | -- | 7.07 | -0.20 | 0.77 |
|
Profit before Tax
|
-20.62 | -474.14 | 335.68 | 257.52 | -206.49 |
|
Provision for Tax
|
-0.39 | 7.30 | 52.87 | 49.76 | 2.78 |
|
Profit after Tax (Net Income)
|
-20.62 | -481.45 | 282.81 | 207.77 | -205.28 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Consolidated Profit
|
0.00 | -583.19 | 245.37 | 182.28 | -205.28 |
Liabilities ($ Mln)
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.92 | -145.70 | 558.95 | 2,263.91 | 271.34 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.82 |
|
Non-Current Liabilities
|
0.20 | 234.78 | 172.75 | 284.17 | 372.93 |
|
Current Liabilities
|
4.74 | 736.51 | 925.13 | 394.28 | 105.46 |
|
Total Liabilities
|
8.59 | 825.59 | 1,656.83 | 2,942.36 | 765.55 |
Assets ($ Mln)
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2.73 | 122.87 | 1,063.00 | 1,624.40 | 346.03 |
|
Current Assets
|
3.13 | 702.72 | 593.83 | 1,317.96 | 419.52 |
|
Total Assets
|
8.59 | 825.59 | 1,656.83 | 2,942.36 | 765.55 |
|
Total Debt*
|
0.00 | 743.06 | 142.12 | 189.94 | 383.50 |
|
Net Current Assets
|
-1.61 | 505.38 | -331.30 | 923.68 | 110.03 |
Cashflow ($ Mln)
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-31.43 | -467.36 | 433.37 | 333.32 | -153.89 |
|
Cash Flow from Investing Activities
|
-0.04 | 286.47 | -34.63 | -26.96 | -96.16 |
|
Cash from Financing Activities
|
0.00 | 134.29 | -182.64 | -546.05 | 253.05 |
|
Net Cash Inflow / Outflow
|
-- | -- | -426.47 | -161.21 | -76.36 |
Ratios
Profitability Ratios
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-175.29 | -65.14 | 44.32 | 8.10 | -36.17 |
|
ROE (%)
|
-930.73 | -818.43 | 59.83 | 8.74 | -61.29 |
|
ROA (%)
|
-102.22 | -50.27 | 18.80 | 6.91 | -28.17 |
|
EBIT Margin (%)
|
-630.85 | -- | -- | -- | -- |
|
Net Margin (%)
|
-972.24 | -180.51 | 15.00 | 11.35 | -85.27 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 4.21 | 0.29 | 0.14 | -0.01 |
|
EBIT Growth (%)
|
72.82 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
57.60 | 17.45 | 15.26 | 13.98 | -16.31 |
|
EPS Growth (%)
|
61.94 | 0.18 | 0.17 | 0.18 | -0.15 |
|
Book Value Growth (%)
|
-95.91 | -- | -- | -- | -- |
Valuation Ratios
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.07 | -14.81 | 34.49 | 36.14 | -14.05 |
|
Price / Book Value
|
0.67 | -48.94 | 17.45 | 3.32 | 10.63 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.08 | -18.18 | 26.63 | 23.67 | -16.30 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -5.10 | 0.25 | 0.08 | 1.41 |
|
Short term debt to equity ratio
|
0.00 | -2.99 | 0.52 | 0.01 | 0.04 |
|
Current Ratio
|
0.66 | 0.95 | 0.64 | 3.34 | 3.98 |
|
Quick Ratio
|
0.66 | 0.67 | 0.64 | 3.30 | 3.07 |
|
Interest Coverage
|
0.92 | -9.76 | 688.87 | 3.75 | -10.27 |
Operating Efficiency Ratios
| Neximmune Inc (NEXI) | Ascendis Pharma A/S - ADR | Medpace Holdings (MEDP) | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 13.45 | 15.82 | 12.97 | 0.00 |
|
Asset Turnover
|
0.11 | 0.28 | 1.25 | 0.61 | 0.33 |
|
Receivable days
|
-- | 32.72 | 53.44 | 45.12 | 1.07 |
|
Inventory Days
|
-6.94 | 1,397.01 | 0.00 | 127.43 | -631.91 |
|
Payable days
|
661.69 | 804.62 | 8.71 | 167.24 | 566.22 |
|
Cash Conversion Cycle
|
-- | 625.11 | 44.73 | 5.31 | -1,197.07 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
